Background: Cirrhosis often remains silent until decompensation, after which survival deteriorates sharply. Contemporary, transition-aware estimates are limited, especially in Asian-predominant cohorts. We analyzed trajectories from compensated advanced chronic liver disease (cACLD) through sequential decompensations t...
E. Tan, N. S. Tang, N. Syn et al.· Hepatology Communications· 0 citations
BACKGROUND & AIMS
Pharmacological trials in sarcopenia have reported changes in muscle mass or selected functional measures, but the consistency and clinical importance of these effects remain uncertain. We conducted a systematic review and pairwise meta-analysis of randomized controlled trials (RCTs) in adults aged ≥6...
Tsubasa Tsutsumi, Saori Hieda, Mirudhula Gnanavelou et al.· Metabolism: Clinical and Exp...· 0 citations
BACKGROUND
Identifying people with at-risk metabolic dysfunction-associated steatohepatitis (MASH) is a major challenge. We aimed to use deep learning to develop a convolutional neural network (CNN) model to facilitate the detection of at-risk MASH.
METHODS
A multi-center cohort study was conducted across five tertia...
Vigneshwaran Selvakumar, J. Low, N. S. Tang et al.· Journal of Gastroenterology...· 0 citations
CKD-related outcomes were more strongly associated with the burden of cardiometabolic abnormalities than with hepatic steatosis itself, and these associations were consistent in individuals with and without SLD.